Data / Research funding / Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy: 35 NIH awards ($40.5M) to 20 organizations
35 NIH awards ($40.5M) in the NIH spending category Facioscapulohumeral Muscular Dystrophy, to 20 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
35 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Novel therapeutics for FSHD | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $3,829,831 | September 10, 2008 | May 31, 2024 | EMERSON, CHARLES P. | reporter.nih.gov |
| A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,123,687 | September 20, 2021 | August 31, 2027 | SALEH, ANTHONY D | reporter.nih.gov |
| CRISPR-Cas13 gene therapy and RNA editing for Facioscapulohumeral muscular dystrophy (FSHD) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,896,188 | August 15, 2021 | July 31, 2026 | HARPER, SCOTT Q | reporter.nih.gov |
| Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $2,857,598 | September 30, 2003 | August 31, 2024 | THORNTON, CHARLES A | reporter.nih.gov |
| CRISPR-inhibition for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,634,755 | August 4, 2021 | June 30, 2027 | JONES, PETER L | reporter.nih.gov |
| Probing the activity of DUX4 in FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,367,457 | March 19, 2010 | July 31, 2030 | KYBA, MICHAEL | reporter.nih.gov |
| Mechanisms of DUX4 mediated FSHD pathology | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $2,366,738 | July 3, 2013 | December 31, 2025 | JONES, PETER L | reporter.nih.gov |
| Genetic and epigenetic mechanisms of FSHD pathogenesis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,340,177 | September 1, 2017 | May 31, 2027 | YOKOMORI, KYOKO | reporter.nih.gov |
| Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,303,547 | August 20, 2024 | July 31, 2029 | STATLAND, JEFFREY | reporter.nih.gov |
| D4Z4 Coding Transcripts and FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,082,296 | September 1, 1998 | December 31, 2026 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| 5-methylcytosine oxidation in development and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,060,740 | May 15, 2021 | December 31, 2026 | PFEIFER, GERD P | reporter.nih.gov |
| Mapping the non-coding RNA landscape in skeletal muscle health and disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2025 | $1,452,283 | April 17, 2023 | March 31, 2029 | COSGROVE, BENJAMIN DAVID | reporter.nih.gov |
| SMCHD1 Pathways as Candidate Targets for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $1,429,596 | April 25, 2014 | June 30, 2025 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| To explore the molecular and cellular effects of transient DUX4 expression in skeletal muscle | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,319,670 | September 1, 2022 | June 30, 2027 | BOSNAKOVSKI, DARKO | reporter.nih.gov |
| Mechanism of Mitochondria-induced Progressive Muscle Wasting | NIH | National Institute on Aging | 2021 to 2023 | $1,190,088 | January 1, 2019 | November 30, 2025 | CHEN, XIN JIE | reporter.nih.gov |
| Mechanisms of DUX4-induced misregulation of RNA processing and quality control | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 to 2025 | $1,028,342 | August 1, 2024 | May 31, 2029 | JAGANNATHAN, SUJATHA | reporter.nih.gov |
| D4Z4 Coding Transcripts and FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $696,022 | September 1, 1998 | March 31, 2022 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| Investigating membrane repair capacity in facioscapulohumeral muscular dystrophy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $490,875 | March 6, 2021 | February 29, 2024 | CHEN, YI-WEN | reporter.nih.gov |
| Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $453,073 | May 13, 2022 | May 31, 2023 | TAWIL, RABI | reporter.nih.gov |
| Chromatin remodeling gene therapy for FSHD using split-vector AAV SMCHD1 vectors | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2022 | $395,224 | July 15, 2021 | June 30, 2024 | HARPER, SCOTT Q | reporter.nih.gov |
| Investigating proteostasis in facioscapulohumeral muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $382,644 | July 1, 2022 | May 31, 2025 | CHEN, YI-WEN | reporter.nih.gov |
| Functional and mechanistic analysis of FSHD myocytes | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $379,940 | September 22, 2021 | August 31, 2024 | YOKOMORI, KYOKO | reporter.nih.gov |
| Accessible FSHD diagnostics through epigenetic analysis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $365,902 | February 1, 2022 | January 31, 2025 | JONES, PETER L | reporter.nih.gov |
| AAV mediated gene knockdown of PIK3C2B as a therapeutic strategy for X-linked myotubular myopathy and fatty liver disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 to 2024 | $322,121 | July 18, 2023 | June 30, 2025 | HARPER, SCOTT Q | reporter.nih.gov |
| Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes | NIH | National Center for Advancing Translational Sciences | 2025 | $313,372 | August 7, 2025 | July 31, 2026 | CHEN, YI-WEN | reporter.nih.gov |
| Development of a direct DUX4 inhibitor for Facioscapulohumeral Muscular Dystrophy (FSHD) | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 | $299,591 | September 1, 2022 | August 31, 2024 | OZES, ALI RAYET | reporter.nih.gov |
| SMCHD1 Pathways as Candidate Targets for FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 | $261,057 | April 25, 2014 | March 31, 2022 | TAPSCOTT, STEPHEN J | reporter.nih.gov |
| STARFISH PIER: Study of Testosterone and rHGH in FSHD: Planning Infrastructure Execution and Readiness | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2024 | $203,280 | February 5, 2024 | April 30, 2025 | HEATWOLE, CHAD RYDEL | reporter.nih.gov |
| The Role of Alternative Splicing in FSHD Disease Models | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $175,500 | September 1, 2025 | July 31, 2030 | KNOX, RENATTA | reporter.nih.gov |
| Exploring the role of hypoxia signaling and its inhibition as a therapy for Facioscapulohumeral muscular dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2023 | $143,574 | April 1, 2022 | March 31, 2024 | COHEN, JUSTIN | reporter.nih.gov |
| Consequence of human satellite repeat expression and immunostimulatory potential in FSHD | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2025 | $124,308 | September 15, 2025 | August 31, 2027 | ARENDS, TESSA AMANDA | reporter.nih.gov |
| Reactivation of an early embryonic program in FSHD and cancer | NIH | National Cancer Institute | 2022 to 2023 | $115,698 | December 1, 2020 | November 30, 2023 | HAMM, DANIELLE | reporter.nih.gov |
| A Long-read Sequencing Approach for Investigating Repeat Number and DNA Methylation of the D4Z4 Region | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $89,250 | February 1, 2020 | January 31, 2023 | CHEN, YI-WEN | reporter.nih.gov |
| Reactivation of an early embryonic program in FSHD and cancer | NIH | National Cancer Institute | 2022 | $23,676 | December 1, 2020 | March 31, 2022 | HAMM, DANIELLE | reporter.nih.gov |
| Advances in Skeletal Muscle Growth, Repair and Disease | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2023 | $15,000 | April 1, 2023 | March 31, 2024 | KYBA, MICHAEL | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Board of Regents, NSHE, obo University of Nevada, Reno | Reno, NV | 3 | $5.4 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 1 | $3.8 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 4 | $3.8 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 2 | $3.7 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 3 | $3.6 million | 0 | $0 |
| University of Rochester | Rochester, NY | 3 | $3.5 million | 0 | $0 |
| Mirecule, Inc. | Gaithersburg, MD | 1 | $3.1 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 2 | $2.7 million | 0 | $0 |
| University of Kansas Medical Center | Kansas City, KS | 1 | $2.3 million | 0 | $0 |
| Van Andel Research Institute | Grand Rapids, MI | 1 | $2.1 million | 0 | $0 |
| Cornell University | Ithaca, NY | 1 | $1.5 million | 0 | $0 |
| Upstate Medical University | Syracuse, NY | 1 | $1.2 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $1 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 3 | $980,755 | 0 | $0 |
| Children's Research Institute | Washington, DC | 3 | $962,769 | 0 | $0 |
| D4Z4 Medicine, Inc. | Bethesda, MD | 1 | $313,372 | 0 | $0 |
| Altay Therapeutics, Inc. | San Carlos, CA | 1 | $299,591 | 0 | $0 |
| Washington University | Saint Louis, MO | 1 | $175,500 | 0 | $0 |
| Yale University | New Haven, CT | 1 | $143,574 | 0 | $0 |
| Society for Muscle Biology | Rockville, MD | 1 | $15,000 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 14 | $7,408,817 | 0 | $0 |
| 2024 | 14 | $7,455,183 | 0 | $0 |
| 2023 | 18 | $7,131,314 | 0 | $0 |
| 2022 | 23 | $9,531,527 | 0 | $0 |
| 2021 | 17 | $9,006,259 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.